Delcath Systems Q1 revenue rises to $25.0 million; net loss of $1.1 million
Delcath Systems reported first-quarter 2026 total revenue of $25.0 million, up from $19.8 million a year earlier, driven by HEPZATO KIT sales of $23.3 million. The company swung to a net loss of $1.1 million from net income of $1.1 million, as research and development and SG&A expenses rose, and adjusted EBITDA fell to $3.4 million from $7.6 million. The company reaffirmed a 2026 outlook of at least $100 million in CHEMOSAT and HEPZATO KIT revenue, with positive adjusted EBITDA.
Key points
- Total revenue of $25.0 million for the quarter ended March 31, 2026, versus $19.8 million a year earlier
- Net loss of $1.1 million, compared with net income of $1.1 million in the first quarter of 2025
- Adjusted EBITDA of $3.4 million, compared with $7.6 million; cash and investments of $89.3 million at March 31, 2026
- 2026 guidance: total CHEMOSAT and HEPZATO KIT revenue of at least $100 million and positive adjusted EBITDA
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.